Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?
| Autor: | Jia-Ning Zhu, Liu-Yan Nie, Hua-Xiang Wu, Xiao-Yong Lu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Clinical Biochemistry MEDLINE Immunologic Tests Cochrane Library Peptides Cyclic Anti-Citrullinated Protein Antibodies Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Rheumatoid Factor Internal medicine medicine Humans Vimentin Rheumatoid factor 030203 arthritis & rheumatology business.industry Biochemistry (medical) Area under the curve General Medicine medicine.disease 030104 developmental biology Rheumatoid arthritis Meta-analysis Biomarker (medicine) Female Differential diagnosis business |
| Zdroj: | Clinical Chemistry and Laboratory Medicine (CCLM). 57:1668-1679 |
| ISSN: | 1437-4331 1434-6621 |
| DOI: | 10.1515/cclm-2019-0167 |
| Popis: | Background Previous reviews of the diagnosis for rheumatoid arthritis (RA) have not compared anti-mutated citrullinated vimentin (MCV) with anti-cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) in respect of sensitivity, specificity and the area under the curve (AUC) against disease controls for differential diagnosis. This meta-analysis aims to evaluate the value of anti-MCV in the diagnosis for RA, the combined sensitivity of anti-MCV and anti-CCP, and certain clinical characteristics related to the performance of anti-MCV. Methods Medline, Embase, Cochrane Library and Web of Science were searched for articles published up to 25 August 2018. A total of 33 studies including 6044 RA patients and 5094 healthy or disease controls achieved inclusive criteria. QUADAS-2 was applied to evaluate the quality of the included studies. The bivariate random effects model was employed in primary data synthesis to evaluate the diagnostic performance. Results The sensitivity of anti-MCV, anti-CCP and RF in RA diagnosis against a disease control group was 0.71, 0.71, 0.77, with the specificity of 0.89, 0.95, 0.73, and the AUC of the SROC of 0.89, 0.95, 0.82, respectively. The predesign of the primary study and diagnostic criteria were statistically significant as sources of heterogeneity. Anti-MCV and anti-CCP tests demonstrated a sensitivity of 0.77 when performed in parallel, with a sensitivity of 0.60 when performed in series; whereas, the combination of anti-MCV and RF presented a sensitivity of 0.64 when used in series. Conclusions Anti-MCV demonstrates comparable diagnostic value to anti-CCP and RF, thus it can be an effective diagnostic marker for RA and may be written into the next authoritative criteria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|